Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: Potential application in vaccine and therapeutical developments

References

• McConnel MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15(11):1022–1033.
   PubMed Web of Science ®Google Scholar
• Dormond E, Perrier M, Kamen A. From the first to the third generation adenoviral vectors: what parameters governing the production yield. Biotech Adv 2008.
   PubMed Web of Science ®Google Scholar
• Grillot-Courvalin C, Goussard S, Courvalin P. Bacteria as gene delivery vectors for mammalian cells. Curr Opin Biotech 1999;10:477–481.
   PubMed Web of Science ®Google Scholar
• Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006;208:290–298.
   PubMed Web of Science ®Google Scholar
• Scott CC, Botelho RJ, Grinstein S. Phagosome maturation: a few bugs in the system. J Membr Biol 2003;193(3):137–152.
   PubMed Web of Science ®Google Scholar
• Dulcos S, Desjardins M. Subversion of young phagosome: the survival strategies of intracellular pathogens. Cell Microbiol 2000;2(5):365–377.
   PubMed Web of Science ®Google Scholar
• Pizarro-Cerdà J, Cossart P. Subversion of cellular functions by Listeria monocytogenes. J Pathol 2006;208(2):215–223.
   PubMed Web of Science ®Google Scholar
• Cornelis GR. The type III secretion injectisome. Nat Rev Microbiol 2006;4:811–825.
   PubMed Web of Science ®Google Scholar
• Parsot C. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol Lett 2005;252(1):11–18.
   PubMed Web of Science ®Google Scholar
• Galàn JE, Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion machines. Nature 2006;444(7119):567–573.
   PubMed Web of Science ®Google Scholar
• Williams MA, Bevan MJ. Effector and memory CTL differentiation. Ann Rev Immunol 2007;25:171–192.
   PubMed Web of Science ®Google Scholar
• Titball RW. Vaccines against intracellular bacterial pathogens. Drug Discov Today 2008;13(13–14):596–600.
   PubMed Web of Science ®Google Scholar
• Good MF, Stanisic D, Xu H, Elliott S, Wykes M. The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunol Rev 2004;201:254–267.
   Google Scholar
• Von Stebut E, Udey MC. Requirement for Th1-dependant immunity against infection with Leishmania major. Microbes Infect 2004;6(12):1102–1109.
   PubMedGoogle Scholar
• Chamekh M. CD40-CD40L interaction in immunity against protozoan infections. J. Biomed Biotech 2007;1–6.
   Google Scholar
• Verhoeven D, Teijaro JR, Farber DL. Heterogeneous memory T cells in anti-viral immunity and immunopathology. Viral Immunol 2008;21(2):99–113.
   PubMed Web of Science ®Google Scholar
• Kennedy R, Celis E. Multiple role for CD4 positive cells in anti-tumor immune vaccine. Immunol Rev 2008;222:129–144.
   PubMed Web of Science ®Google Scholar
• Gomez CE, Nàjera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccine against infectious diseases and cancer. Curr Gene Ther 2008;8(2):97–120.
   PubMed Web of Science ®Google Scholar
• Ferreira TB, Alves PM, Aunins JG, Carrondo MJ. Use of adenoviral vectors as veterinary vaccines. Gene Ther 2005;12:73–83.
   PubMed Web of Science ®Google Scholar
• Reyers-Sandoval A, Harty JT, Todryk SM. Viral vectors vaccines make memory T cells against malaria. Immunology 2007;121(2):158–165.
   PubMed Web of Science ®Google Scholar
• Glover DJ, Lipps HJ, Jans DA. Toward safe, non viral therapeutic gene expression in humans. Nature Rev Genet 2005;6:299–310.
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Intern Immunol 2005;17(1):1–14.
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442:39–44.
   PubMed Web of Science ®Google Scholar
• Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997;91(6):765–775.
   PubMed Web of Science ®Google Scholar
• Rüssmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RP. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998;281:565–568.
   PubMed Web of Science ®Google Scholar
• Panthel K, Meinel KM, Sevil Domènech VE, Trülzsch K, Rüssmann H. Salmonella type III-mediated heterologous antigen delivery: A versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Intern J Med Microbiol 2008;298:99–103.
   PubMed Web of Science ®Google Scholar
• Evans DT, Chen LM, Gillis J, Lin KC, Harty B, Mazzara GP et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 2003;77(4):2400–2409.
   PubMed Web of Science ®Google Scholar
• Rüssmann H, Igwe EI, Sauer J, Hardt WD, Bubert A, Geginat G. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 2001;167:357–365.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Lankowski AJ, Scott N, Sisul D, Chen LM, Raschke K et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella type III secretion system. Vaccine 2006;24:6216–6224.
   PubMed Web of Science ®Google Scholar
• Tartz S, Rüssmann H, Kamanova J, Sebo P, Sturm A, Heussler V et al. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine 2008;26(47):5935–5944.
   PubMed Web of Science ®Google Scholar
• Lotter H, Rüssmann H, Heesemann J, Tannich E. Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis. Intern J Med Microbiol 2008;298:79–86.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006;116:1946–1954.
   PubMed Web of Science ®Google Scholar
• Panthel K, Meinel KM, Sevil Domènech VE, Geginat G, Linkemann K, Busch DH et al. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. Microbes Infect 2006;8:2539–2546.
   PubMedGoogle Scholar
• Epaulard O, Derouazi M, Margerit C, Marlu R, Filopon D, Polack B et al. Optimization of a type III secretion system-based Pseudomonas aeruginosa live vector for antigen delivery. Clin Vaccine Immunol 2008;15(2):308–313.
   PubMedGoogle Scholar
• O’Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowiks C. Strategies for use of IL-10 or its antagonist in human disease. Immunol Rev 2008;223:114–131.
   PubMed Web of Science ®Google Scholar
• Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB. IL-10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996;38:836–845.
   Google Scholar
• Arend WP. IL-1 receptor antagonist. Adv Immunol 1993; 54:167–227.
   PubMed Web of Science ®Google Scholar
• Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103:65–77.
   PubMed Web of Science ®Google Scholar
• Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous IL-10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997;133:383–389.
   Google Scholar
• Schreiber S, Fedoral RN, Nielsen OH, Wild J, Williams CN, Nikolaus S et al. Safety and efficacy of recombinant human IL-10 in chronic active Crohn’s disease: Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461–1472.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Gangl A, Elson CO, Rutqeerts P, Schreiber S, Wild J et al. Recombinant human IL-10 in the treatment of patients with mild to moderately active Crohn’s disease: the IL-10 inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119:1473–1482.
   PubMed Web of Science ®Google Scholar
• Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W et al. Treatment of murine colitis by Lactococcus lactis secreting IL-10. Science 2000;289:1352–1355.
   PubMed Web of Science ®Google Scholar
• Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ. Local delivery of adenoviral vectors encoding murine IL-10 induces colonic IL-10 production and is therapeutic for murine colitis. Gut 2003;52:981–987.
   PubMed Web of Science ®Google Scholar
• Chamekh M, Phalipon A, Quertainmont R, Salmon, I, Sansonetti P, Allaoui A. Delivery of biologically active anti-inflammatory cytokines IL-10 and IL-1ra in vivo by the Shigella type III secretion system. J Immunol 2008;180(6):4292–4298.
   PubMed Web of Science ®Google Scholar
• D’hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, Mathison J, Ulevitch RJ, Wuscher N, Parsot C, Sansonetti PJ. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002;168:5240–5251.
   PubMed Web of Science ®Google Scholar
• Zychlinsky A, Sansonetti PJ. Apoptosis as a proinflammatory event: what can we learn from bacteria-induced cell death? Trends Microbiol 1997;5:201–204.
   PubMed Web of Science ®Google Scholar
• Arondel J, Singer M, Matsukawa A, Zychlinsky A, Sansonetti PJ. Increased IL-1 and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental shigellosis. Infect Immun 1999;67:6056–6066.
   PubMed Web of Science ®Google Scholar
• Andus T, Daig R, Vogel D. Imbalance of the IL-1 system in colonic mucosa: association with intestinal inflammation and IL-1 receptor antagonist genotype 2. Gut 1997;41:651–657.
   PubMed Web of Science ®Google Scholar
• Coster TS, Hoge CW, Van De Verg LL, Hartman AB, Oaks EV, Venkatesan MM et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999;67:3437–3443.
   PubMed Web of Science ®Google Scholar
• Singer M, Sansonetti PJ. IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 2004;173(6):4197–4206.
   PubMed Web of Science ®Google Scholar
• Fernandez MI, Thuizat A, Pedron T, Neutra M, Phalipon A et al. A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell Microbiol 2003;5(7):481–491.
   PubMed Web of Science ®Google Scholar